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ABSTRACT
Introduction: Macrocephaly, defined as a head circumference more than two standard deviations from the normal distribution, 
is among the most frequently requested neuropediatric consultations.
Materials: we conducted a retrospective study on 189 subjects with macrocephaly, from birth to 18 years old, enrolled from 
October 2001 to December 2019, for diagnostic definition and/or neurodevelopmental assessment. Brain sonography has been 
performed in all infants and CT or MR in selected patients.
Results: macrocephaly was prevalent in males (62.4%), a head circumference >3SD (8.5%) has been associated with a 
neurodevelopmental impairment. A genetic and/or concomitant malformation were present in 11.1% of the sample. A male prevalence 
for impaired outcome has been ascertained.
Conclusions: early identification of pathological macrocephaly is necessary to plan a possible treatment, an individualized and 
multidisciplinary follow up and an effective genetic counseling.
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Introduction
In early infancy the open cranial fontanels and 
the not fused together skull bones allow for brain 
growth. The higher increase in head growth takes 
place antenatally and in the first three months of life. 
The rate of increase in head circumference is about 
3cm per month. Between 4-6 years of age the head 
circumference increases around by one cm per year. 
Expansion of one compartment is at the expense of 
another. The measurement of head circumference 
(HC) is a direct reflection of head growth and has 
been adopted as an important step in the evaluation 
of childhood growth and development(1). In the last 
years increased prenatal diagnosis by ultrasound 
examination and fetal MR has deeply changed the 
perinatal management of fetal macrocephaly, and 
allowed intrauterine surgical intervention in case 
of prenatal hydrocephalus(2, 3). It is basilar to differ-
entiate between an increased HC related to the in-
creased thickness of the skull bones, intracerebral 
cerebrospinal fluid, intracerebral blood collection 
or arteriovenous malformation, and megalencephaly 
(increased brain parenchyma). A diagnostic flow-
chart, including the previous described conditions, 
is reported (Figure 1).
From birth until cranial fontanels are not ossi-
fied, brain sonography and transcranial doppler are 
able to identify benign enlargement of subarachnoid 
spaces (BESS), intraventricular hemorrhage, megal-
encephaly, hydrocephalus, arachnoid cysts, and sus-
pect an arterio-venous malformation(4).
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Neonatal metabolic screenings allow early de-
tection of genetic disorders responsible for metabol-
ic megalencephaly in a pre-symptomatic phase(5). 
Brain MR and angiography are preferred in develop-
mental age to confirm and/or diagnose parenchymal 
involvement as well as brain and vascular malfor-
mations, while brain CT is the imaging technique of 
choice in the setting of acute head trauma(6). About 
2.4 % of general population is macrocephalic often 
with a familial tendency. Online Mendelian Inher-
itance in Man (OMIM), the most authoritative com-
pendium of human genes and genetic phenotypes, 
currently reports 458 entries for macrocephaly and 
49 entries for megalencephaly(7). The diagnostic 
and therapeutic management depends on the over-
all clinical and risk profiles. Different scenarios can 
be outlined in relation to the age of assessment, the 
level of clinical impairment, the urgency for a thera-
peutic intervention and genetic counseling as well as 
the planning for an individualized multidimensional 
follow-up.  
Materials and methods
 
We conducted a retrospective study on 189 sub-
jects enrolled from October 2001 to December 2019 
at the University Department including a Neonatal 
Intensive Care Unit, a Nursery and a Neurological 
and Follow-Up Unit. Inclusion criteria, for both in-
born and outborn patients, have been a prenatal or 
postnatal suspected brain imaging and/or a suspicion 
of abnormal development associated to macroceph-
aly. Brain sonography and transcranial doppler have 
been performed at the first evaluation, then repeated 
during the follow-up. Brain and doppler sonography 
have been executed by EP and allowed to differen-
tiate between enlarged ventricles, intraparenchymal 
cysts and BESS. Brain MR, electroencephalogra-
phy (EEG), and flash visual evoked potentials (flash 
VEP) has been performed in selected cases. 
From 2001 audiologic evaluation has been per-
formed in selected cases, while from 2015 an audi-
ological neonatal screening by evoked otoacoustic 
emissions (EOAE) has been performed in all new-
borns with an eventual final diagnosis by auditory 
brain stem response (ABR). For the developmental 
evaluation and diagnosis, both screening test (Den-
ver DST I-II) and standardized assessment tools 
(Brunet-Lezine, McCarthy Scales of Children's 
Abilities, Bayley Scales of Infant Development II-III, 
ELMS I-II, WPPSI and WISSC) have been adopted. 
The age of enrollment ranged from birth, including 
subjects with prenatal diagnosis of macrocephaly, to 
18 years of age. All the subjects included in the study 
have been selected from the general database of the 
follow-up Unit including about 2500 subjects. 
In the study we have included only inborns with 
prenatal diagnosis of a pathological condition, or ev-
idence of clinical signs of suspicion or pathological 
brain sonography. Patients more than 18 years of 
age, already included in a previous study on Neu-
rofibromatosis type 1, have been excluded(8). Written 
parental consent for the enrollment in the follow-up 
activity has been obtained at birth or at the moment 
of the first clinical evaluation. 
Results
The adopted chronological age intervals at 
enrollment have been: 0-6 months; 7-12 months; 
2-4 years; 5-18 years, accounting for 83 (43.9%), 
47 (24.9%), 33 (17.5%) and 26 (13.7%) subjects re-
spectively. The sample has been characterized by a 
male prevalence (62.4%), and a high prematurity rate 
(11.6%). HC has been >3 DS in the 8.5% of the sam-
ple and always associated to a severe neurodevelop-
mental impairment/autism. A genetic, metabolic or 
concomitant malformation have been identified in 
11.1% of subjects. A various degree of developmen-
tal delay/intellectual disability or confirmed autism 
affected 31.4% of the 169 subjects aged more than 2 
years on March 2018. We considered that before this 
age is still present the possibility of some neurofunc-
tional recovery. 
A worse developmental outcome in male pa-
tients has been ascertained (Table 1). 
N° %
Males 118/189 62.4
Prematurity 22/189 11.6
HC >2SD 173/189 91.5
HC >3SD 16/189 8.5
Genetic/metabolic/associated malformation 21/189 11.1
Developmental delay/Intellectual disability/Autism       
Evaluated  >2y age 53/169 31.4
Males 39/53 73.6
Table 1: Anthropometric, and clinical data of the sample.
Figure 1: Diagnostic flow-chart for macrocephaly.
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Discussion
This study has allowed us to explore and out-
line some different scenarios characterizing mac-
rocephaly. In our sample the prematurity birth rate 
has been superior to the actual mean Italian rate 
(7.79%(9). Prenatally diagnosed macrocephaly, sec-
ondary to fetal posthemorrhagic hydrocephalus or 
myelomeningocele, underwent ventriculoperitoneal 
derivation(10). Benign familial macrocephaly (OMIM 
# 153470) has been frequently associated to a male 
to male transmission with a generally normal neu-
rodevelopmental profile. An isolated macrocephaly 
concomitant to BESS has been diagnosed in the first 
months of life by brain sonography and frequently 
showed a progressive recovery from a concomitant 
mild gross motor delay(11).
Since in Western Sicily our University Depart-
ment is the referral center for genetic and congen-
ital pathologies, some genetic conditions correlated 
to megalencephaly have been identified; as Costello 
Syndrome, PTEN related autism, NF1, and rare ge-
netic syndromes(12, 13, 14, 15, 16). Nevertheless, the chang-
ing panorama and availability of molecular genetic 
investigations during the 18 years of the survey make 
difficult to draw clear global conclusions. 
Early detection of neurosensorial impairment 
has allowed an early treatment in affected subjects(17). 
The male prevalence for developmental delay and au-
tism has been recently confirmed(18), and has been ex-
plained by the concept of “female protective model”, 
which considers the higher mutation burden present 
in females as a protective factor(19). We conclude con-
firming that a strict monitoring of HC, starting from 
intrauterine growth assessment, is basilar for early 
diagnosis and the following planning for individual-
ized treatment and a multidimensional neurodevel-
opmental follow-up.
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